EGFR and neoplasm: They also found that patients with a higher quantity of tumor-associated molecules (e.g., EGFR, EGFRvIII, podoplanin) in their EVs were more likely to fail standard of care therapy with chemoradiation (radiotherapy plus temozolomide) [130,140].